A 38-year-old woman with stage IIIB cervical cancer (parametrial involvement, no distant metastases) is deemed a candidate for neoadjuvant chemotherapy followed by radical hysterectomy and pelvic lymphadenectomy. Which chemotherapy regimen is the preferred first-line choice?